新辅助化疗可以提高胃癌手术根治性切除率，改善病人预后。MAGIC等研究均证实了围手术期化疗的有效性和安全性，使之成为相关指南推荐的治疗方式。新辅助化疗的深入研究不仅要关注其远期效果，还应考虑应用某种方案时对于手术本身的影响。目前关于这方面的研究报道不是很多，继续开展一些高质量的临床研究，准确评估治疗风险，进一步提高胃癌新辅助化疗的疗效和手术安全性，将是今后进展期胃癌研究的热点。

Complications after radical gastrectomy following neoadjuvant chemotherapy for gastric cancer        LI Zi-yu, JI Xin, JI Jia-fu. Department of Gastrointestinal Surgery, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing100142, China
Corresponding author: LI Zi-yu, E-mail: ligregory369@hotmail.com
Abstract    The concept of neoadjuvant chemotherapy has been widely accepted recently for the benefit of increasing the R0 resection rate and the long-term survival in patients with gastric cancer. To date, owing to the results of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial, perioperative chemotherapy for locally advanced resectable gastric cancer has become a grade A recommendation. There are limited data available regarding postoperative morbidity and mortality in patients performed neoadjuvant chemotherapy for gastric cancer. If neoadjuvant chemotherapy is going to be considered as a therapeutic option in patients with locally advanced gastric cancer, it is necessary to verify that it can be delivered safely without an increase in postoperative morbidity and mortality.